Inhaled fluticasone furoate falls flat in speeding up COVID-19 recovery, says ACTIV-6 trial

The ACTIV-6 trial investigated the effectiveness of inhaled fluticasone furoate on mild-to-moderate COVID-19 cases and found it did not accelerate recovery or prevent clinical progression compared to a placebo. Interestingly, vaccinated participants showed slightly faster recovery when treated with the drug, while unvaccinated participants did not.

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference | Psychedelic Invest

atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald

September 28, 2023

California pushes to expand the universe of abortion care providers

California’s efforts to expand access to abortion care are enabling more types of medical practitioners to perform certain abortion procedures — potentially a boon for

March 4, 2024

Early Data for GLP-1 Pill; FAERS Tirzepatide Reports; AI Diabetes Voice Screening

Studies presented at the European Association for the Study of Diabetes (EASD) annual meeting in Madrid included early data for oral amycretin, safety data for

September 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.